Dear Colleagues and Friends,
We are pleased to report that thousands of participants from around the world united once again for the 2022 WuXi Healthcare Forum. This year, we gathered under the theme of “Call To Action” to support the World Health Organization’s key initiatives in tackling global health challenges head-on, and to collaboratively advance better healthcare solutions.
To our esteemed guest speakers, THANK YOU for leading the way with new thinking and actionable approaches as we work together to shape the future of healthcare.
Special thanks to our supportive partners: UK BioIndustry Association, BioCentury, Biocom California, Clarivate, California Life Sciences, Endpoints News, GEN, MBC BioLabs, Medicon Valley Alliance, Pharma Intelligence | Informa, and Swiss Biotech Association.
Please scroll down for the final agenda, or click the links below to watch this Forum on-demand (All day events or individual sessions).
Walter Koroshetz, Director, National Institute of Neurological Disorders & Stroke, National Institutes of Health
A conversation between Harold Burstein, Institute Physician, Dana-Farber Cancer Institute; Professor of Medicine, Harvard Medical School, Arif Kamal, Chief Patient Officer, American Cancer Society; Physician Quality & Outcomes Officer, Duke Cancer Institute, and Tony Mok, Li Shu Fan Professor of Clinical Oncology, The Chinese University of Hong Kong
Erin Duffy, Chief of Research & Development, CARB-X
Valeria Gigante, Team Lead, AMR Division, World Health Organization, Geneva, Switzerland
Timothy Jinks, Head of Infectious Diseases Interventions, The Wellcome Trust
Henry Skinner, CEO, AMR Action Fund
Session Leader: Jenny Yip, Managing Partner, Adjuvant Capital
Stephen Hahn, CEO-Partner, Flagship Pioneering; CEO, Harbinger Health
Rajesh Chopra, Venture Partner, Head of Oncology, Apple Tree Partners
Adam Friedman, President, Corporate Strategy & Business Development, Scorpion Therapeutics
Luba Greenwood, CEO, Kojin Therapeutics
KT Moortgat, Healthcare Venture Investor, Investment Partner, Droia Ventures
Lewis Williams, Co-founder, Chairman & CEO, Walking Fish Therapeutics, Inc.
Session Leader: Dave Madge, VP of Discovery Services, WuXi AppTec
Andrew Bruce, CEO, MediSix Therapeutics
Wee Joo Chng, Executive Director, Singapore Translational Cancer Consortium; Director & Senior Consultant, National University Cancer Institute, Singapore, NUHS
Boon Tong Koh, Executive Director, Bioprocessing Technology Institute, A*STAR, Singapore
Francesca Lim, Assistant Medical Director, Cell Therapy Facility, Health Science Authority (HSA); Senior Consultant Hematologist, Singapore General Hospital
Yann Chong Tan, Managing Director, EVX Ventures; CEO, Nuevocor; CSO, Cargene Therapeutics
Session Leader: Danny Soon, CEO, Consortium for Clinical Research & Innovation, Singapore; Executive Director, Singapore Clinical Research Institute
Opening Remarks by Steve Bates, CEO, UK BioIndustry Association
Billy Boyle, Co-Founder & CEO, Owlstone Medical
Ryan Cawood, CSO, WuXi Advanced Therapies & OXGENE
Kathryn Corzo, COO, bit.bio
Jack O’Meara, CEO, Ochre Bio
Session Leader: Michael Ward, Global Head of Life Sciences & Healthcare Thought Leadership, Clarivate
Dr. Hui Cai joined WuXi AppTec in 2009 as Vice President of Business Development, and is currently Vice President and Head of Content Division.
Prior to WuXi, Dr. Cai spent 10 years at Johnson & Johnson Pharmaceutical Research and Development leading multiple drug discovery programs in the therapeutic areas of inflammation and autoimmune diseases. She is a co-author and co-inventor to over 50 scientific publications and issued or pending patents. Dr. Cai is a Councilor of the American Chemical Society (ACS), a member of BayHelix, and a member of the UCSD Alumni Board. In her past capacity, she served as a Commissioner at the City of San Diego Science and Technology Commission, Chair of SABPA, and President of SDCA. Dr. Cai received her BS and MS in Chemistry from Peking University, PhD from The Scripps Research Institute, and MBA from UCSD Rady School of Management as a DLA Piper – Athena Scholar.
Dr. Steve Yang is Co-CEO of WuXi AppTec. He is also WuXi AppTec’ s Head of WuXi Biology and Head of WuXi Testing. His responsibilities include management of multiple business units and commercial operation. WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients.
Dr. Yang is a pharmaceutical industry leader recognized for building R&D and service capabilities, delivering research and early development portfolios of drug candidates, and establishing R&D partnerships in US, Europe, China and other Asian and emerging markets. Before joining WuXi AppTec, Dr. Yang was Vice President and Head of Asia and Emerging Markets iMed at AstraZeneca, based in Shanghai. Previously, Dr. Yang served as Vice President and Head of Asia R&D at Pfizer based in Shanghai, and as Executive Director and head of Pfizer’s global R&D strategic management group based in the United States.
Dr. Yang received his PhD in Pharmaceutical Chemistry from the University of California, San Francisco. He started his undergraduate study in Fudan University, China and completed his BS Summa Cum Laude from Michigan Technological University. He co-founded the BayHelix Group, a non-profit global professional organization of Chinese life science business leaders, and served as the chairman of the board for two terms.
Mene was appointed as Executive Vice-President, R&D BioPharmaceuticals in January 2019 and is responsible for BioPharmaceutical R&D from discovery through to late-stage development covering Cardiovascular, Renal, Metabolism, Respiratory, Immunology, Microbial Science and Neuroscience areas. Prior to this, he served as Executive Vice-President of AstraZeneca’s Innovative Medicines & Early Development Biotech Unit and Global Business Development.
Since joining AstraZeneca in 2010, Mene has led the transformation of R&D productivity through the development and implementation of the “5R” framework resulting in a greater than four-fold increase in success rates compared to industry averages. In parallel, he has championed an open approach to working with academic and other external partners, changing the nature of academic-industry collaboration. Mene previously held senior R&D roles at Wyeth and GSK.
Mene holds Honorary Doctorates from Glasgow University and Imperial College, London, is a Fellow of the Academy of Medical Sciences, the Royal Society of Biology and Clare Hall, University of Cambridge and is a Visiting Professor at The Wolfson Centre at Kings College. He co-chairs the UK Life Sciences Council Expert Group on Innovation, Clinical Research and Data and is a member of the Life Sciences Industrial Strategy Implementation Board. He is also on the Boards of The Francis Crick Institute, The Judge Business School, Cambridge University and Dizal Pharma, and is a member of the Life Sciences Vision Advisory Group. Mene was awarded the 2019 Prix Galien Medal, Greece for his scientific research and named Executive of the Year at the 2019 Scrip Awards. In 2019, Mene was awarded the honour of a Knighthood by Her Majesty The Queen for his services to UK science. In 2021 Mene was awarded an Honorary Fellowship of the British Pharmacological Society.
Mene also oversees the creation of AstraZeneca’s new Global R&D Centre in Cambridge – a state of the art facility designed to stimulate collaborative scientific innovation and which will play an important role in the future success of the UK life science industry which has started occupation this year.
Since the start of 2020, Mene has led and overseen AstraZeneca’s R&D response to COVID-19; maintaining existing clinical trials and delivery of medicines to patients, responding to the UK government’s call for supporting our national testing effort, and discovering and developing new preventative and treatment approaches to the disease. This work has involved partnering with Oxford University in the global development of a vaccine and ensuring broad an equitable access at no profit during the pandemic, the discovery and development of a long-acting antibody combination for those who can’t be vaccinated, as well as exploring our existing portfolio as potential treatment options against the disease.
Emilio A. Emini, Ph.D. is the CEO of the Bill & Melinda Gates Medical Research Institute. He joined the Institute following a six-year tenure at the Bill & Melinda Gates Foundation as the Director of the foundation’s Tuberculosis and HIV Program. Emilio joined the foundation in 2015 following a greater than 30-year career in the biopharmaceutical industry during which he held multiple senior positions in anti-infectives and vaccines R&D. At the Merck Research Laboratories, from 1983 to 2004, Emilio led the biological research that developed the first of the highly active antiretroviral therapies for HIV and led multiple vaccine research teams that participated in the successful development of a number of vaccines, including vaccines for human papillomavirus and rotavirus. Following a two-year leave from the industry at the International AIDS Vaccine Initiative, Emilio joined Wyeth/Pfizer as the Senior Vice President of Vaccine R&D where he led the development of the Prevenar 13 vaccine for prevention of pneumococcal disease. Emilio is a recipient of the Distinguished Alumnus Award from the Cornell University Graduate School of Medical Sciences. He is an elected Fellow of the American Academy of Microbiology, and the College of Physicians of Philadelphia. He is a former Trustee of the National Foundation for Infectious Diseases and served as a member of the National Preparedness & Response Science Board, an advisory committee to the U.S. Secretary of Health and Human Services.
Dr. Zina Affas Besse’s twenty-five years in the healthcare industry to date span healthcare venture capital investment, operational business development and fundraising. Prior to her move to GHIA, Zina was Chief Business Officer at Novintum Bioscience, a small molecule company developing novel drugs for cancer, where she was responsible for fundraising, grant applications and alternative financing solutions including the spin-in of the assets into the University of Oxford. Dr. Affas Besse joined AXA Investment Managers Group (AXA IM Alts) as Deputy Head of Global Health Private Equity in 2022.
Zina previously worked with various healthcare companies supporting them with fundraising and business development. Zina was a co-founder of Orion Healthcare Equity Partners, a start-up life-sciences venture-capital company where she was involved globally in fundraising as well as investment sourcing and structuring. Zina also spent 6 years as a Principal at Atlas Venture in 2002, focusing on the biopharmaceutical and medical device sectors globally, supporting all aspects of deal making. Dr. Zina Affas Besse earned her doctorate in Medicinal Chemistry at the University of Nottingham in 1999 and received her BPharm with honors from the University of Nottingham in 1994.
Dr. Koroshetz serves as Director of the National Institute of Neurological Disorders and Stroke. He joined NINDS in 2007 as Deputy Director and has co-led the NIH’s BRAIN Initiative, the Neuroscience Blueprint, the Traumatic Brain Injury Center with the Uniformed Health Services University, the Helping to End Addiction Long Term (HEAL) Initiative, the Undiagnosed Disease, and the Acute to Chronic Pain Transition Programs, NIH Emergency Care Research and the Post Acute Sequalae of COVID-19 Initiative. Before NINDS, Dr. Koroshetz served as the Neurology Vice Chair and Director of Stroke and Neurointensive Care, led neurology resident training at Massachusetts General Hospital as a Harvard professor.
Dr. Jessup is Chief Science and Medical Officer of the American Heart Association and an Emeritus Professor of Medicine at the University of Pennsylvania School of Medicine.
Dr. Jessup has been a member of the committee for ACC/AHA Guidelines for the Management of Heart Failure since 2001. She served on the European Society of Cardiology’s Heart Failure Guideline writing committee as well. She has served as the Chair of the American Board of Internal Medicine’s (ABIM) Cardiovascular Board, and for two years as the Chair of the Committee for Scientific Sessions Program of the AHA. She was a member of the Board of Directors of the national AHA, and President from 2013-2014. She completed a 4-year term on the Residency Review Committee-Internal Medicine of the ACGME, and a 6-year term on the ABIM’s Cardiovascular Board. She joined the Board of the Advanced Heart Failure and Transplant cardiology secondary subspecialty, and became Chair for two years. She was the Chief Scientific Officer of the Leducq Foundation from January 2017 through August 2018, before moving to the American Heart Association role.
Faiez Zannad is among the Web of Science most highly cited researchers. He has pioneered and made significant contributions to research and care in heart failure. He has mainly contributed to building the evidence supporting modern HF therapy, including mineralocorticoid receptor antagonists, beta-blockers, SGLT2 inhibitors and anticoagulants, as well as in major comorbid conditions in HF, such as sleep-disordered breathing, autonomic nervous dysfunction, diabetes, hyperkalaemia and chronic kidney disease. He is steering several ongoing major HF trials. He implemented successfully the largest HF disease management program in France (ICALOR).
He has served as Chairman of the French Society of Hypertension, Chairman of the ESC Working Group on Pharmacology and Drug Therapy, and as a board member of the HFA of the ESC. He is the founder and chairman of the Global CardioVascular Clinical Trialists (CVCT) Forum and Workshop, an annual international think tank meeting dedicated to the science of clinical trials, with meetings in Paris, Washington DC, Asia and the Middle East.
Harold J. Burstein, M.D., Ph.D. is a medical oncologist and clinical investigator specializing in breast cancer. He is a Professor of Medicine at Harvard Medical School, and Institute Physician at Dana-Farber Cancer Institute. Dr. Burstein attended Harvard College, and earned his MD at Harvard Medical School where he also earned a PhD in immunology. In addition, he holds a master's degree in history of science from Harvard. He trained in internal medicine at Massachusetts General Hospital, and was a fellow in medical oncology at Dana-Farber before joining the staff.
Dr. Burstein’s clinical practice is devoted entirely to breast cancer patients. His clinical research interests include novel treatments for early- and advanced-stage breast cancer, and studies of quality of life and health behavior among women with breast cancer. Dr. Burstein has written widely on breast cancer in both traditional medical journals and on the web. Representative publications of Dr. Burstein’s can be found in the New England Journal of Medicine, JAMA, the Journal of Clinical Oncology, and other leading medical journals. He serves on international committees focusing on cancer treatments including the NCCN Breast Cancer Panel, The St. Gallen Breast Cancer Consensus, and the ESMO Breast Cancer Panel. He is co-chair of the ASCO guidelines on endocrine therapy for breast cancer, and associate editor for cancer education at the Journal of Clinical Oncology. Dr. Burstein teaches students, house staff, and fellows at Harvard Medical School, Dana-Farber, Brigham & Women’s Hospital, and affiliated training hospitals.
Dr. Arif Kamal is the inaugural Chief Patient Officer of the American Cancer Society and an Associate Consulting Professor at the Duke University School of Medicine. He is an internationally-recognize supportive and palliative care thought leader and researcher, with over 200 publications and 15 book chapters on these topics.
Professor Tony S.K. Mok was trained at the University of Alberta, Canada and he subsequently completed a fellowship in medical oncology at the Princess Margaret Hospital in Toronto. After working as a community oncologist in Toronto, Canada for seven years, he returned to Hong Kong in 1996 to pursue an academic career.
Professor Mok is the Li Shu Fan Medical Foundation endowed Professor and Chairman of Department of Clinical Oncology at The Chinese University of Hong Kong. His main research interest focuses on biomarker and molecular targeted therapy in lung cancer. He was the Principal Investigator and first author on the landmark IRESSA® Pan-Asia Study (IPASS), which was the first study that confirmed the application of precision medicine for advanced lung cancer. He has also led and co-led multiple international phase III studies including the FASTACT 2, PROFILE 1014, IMPRESS, ARCHER 1050, ALEX, AURA 3 and KEYNOTE 042. These projects address various aspects on management of advanced lung cancer, and basically have defined the current practice. He dedicates his work on precision medicine for lung cancer by also engaging in clinical research on oncogene driven lung cancer and immunotherapy. His work has been adopted by multiple international guidelines including NCCN, AMP/IASLC/CAP, ASCO and ESMO. He also contributes to the development of clinical research infra-structure in China and Asia. He cofounded the Lung Cancer Research Group, Chinese Thoracic Oncology Research Group and Asia Thoracic Oncology Research Group.
Professor Mok has contributed to over 270 articles in international peer-reviewed journals, including the New England Journal of Medicine, Science, Lancet, Nature Medicine and Journal of Clinical Oncology, and published multiple editorials and textbooks. He served as an Associate Editor for thoracic oncology for the Journal of Clinical Oncology and other international journals. He is the Past President and Past Treasurer of the International Association for the Study of Lung Cancer (IASLC). He is a member of the Board of Directors for ASCO, ACTG-Sanomics Group, AstraZeneca, Aurora Tele-Oncology, HutchMed (China) and St. Stephen’s College & Preparatory School. He is active in international education activity and has made significant contribution to AACR, ASCO, CSCO and ESMO. His work was recognized by numerous awards including Bonnie Addario Award in 2015, Fellowship of the American Society of Clinical Oncology (FASCO) in 2017, Paul Bunn Jr Scientific Award in 2017, National Science and Technology Progress Award in 2017, CSCO Annual Achievement Award in 2017, ESMO Lifetime Achievement Award in 2018, The 6th Kobayashi Foundation Award, Giant of Cancer Care 2020 and SingTao Hong Kong Leader of the Year 2020 Award. His recent article in the New England Journal of Medicine has been selected as one of the most “Notable Articles in 2017.” His is one of the “Highly Cited Researchers” by Clarivate Analytics for four consecutive years from 2018 to 2021.
Jenny is currently a Managing Partner at Adjuvant Capital, a life sciences investment fund dedicated to mid- to late-stage research and development of products addressing significant global health challenges affecting lower- and middle-income countries. Adjuvant’s portfolio spans across drugs, vaccines, medical devices and diagnostics for high-burden infectious disease, sexual and reproductive health. Jenny currently serves on the boards of Antiva Biosciences (US), 54gene (Nigeria) and ChromaCode (US) and as a board observer on Evofem Biosciences (NASDAQ: EVFM) and Excision Biotherapeutics (US).
Prior to Adjuvant, Jenny was a Partner at the Bill & Melinda Gates Foundation Strategic Investment Fund where she led transactions across the foundation’s focus areas in global health, agriculture, nutrition, and education. She has always been passionate about improving the health and lives of those living in low-resourced settings and spent time working in Kenya and China. In Kenya, Jenny was as a volunteer consultant for Technoserve, a non-profit business consultancy for small-holder farmers and small to medium businesses.
Jenny has worked in finance for over 19 years, beginning as an investment banker advising corporate clients in mergers and acquisitions and debt and equity financings at Goldman Sachs’ Hong Kong, New York, and San Francisco offices. She also serves on the Investment Advisory Committee at the Reproductive Health Investors’ Alliance (US).
Jenny graduated magna cum laude from Harvard University with an AB in History of Science. She lives with her husband and two children in San Francisco.
Erin Duffy Jorgensen is the Chief of Research & Development at CARB-X. CARB-X is a global non-profit partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria. CARB-X funds the world’s largest early development pipeline of new antibiotics, vaccines, rapid diagnostics, and other products to prevent, diagnose and treat life-threatening bacterial infections. Prior to CARB-X, she worked at Melinta Therapeutics (fka Rib-X Pharmaceuticals) where she held increasing roles, eventually becoming EVP, Chief Scientific Officer. Erin began her career in the Central Research Labs of Pfizer as a computational chemist and structural biologist. She was trained formally at Yale University in physical-organic chemistry and structural biology.
Dr. Valeria Gigante is a Clinical Pharmacologist and a senior Regulatory Affairs and Health Policy specialist with fourteen years’ experience in public health. She is Team Lead at the World Health Organization (WHO) in the AMR Division where she coordinates research and priority-setting.
Dr. Gigante started her career in Regulatory Affairs in London at the European Medicines Agency (EMA) in 2007 where she worked as Scientific Administrator on safety and efficacy of medicines for human use. She joined the Italian Medicines Agency (AIFA) in 2010 as Clinical Assessor (PK/PD) for EU centralized procedure. She joined the WHO in 2017 where she coordinated the development of WHO guidelines on pharmaceutical regulation.
Dr. Gigante holds a Master Degree in Pharmacy with training in Microbiology and Hygiene and a Ph.D. in Pharmacology and Toxicology on available therapies for MDR-TB.
She has published with the EMA MSWG on advanced methods for dose and regimen finding during development, on MID3 good practices, on scaling dose exposure response and with WHO on Bioequivalence/Biowaiver, AMR. She is currently writing and contributing to several WHO guidelines, policy documents and publications. She collaborates as peer reviewer with the WHO Bulletin.
Dr. Gigante has served as an expert on international experts groups such as the EMA Modeling and Simulation Working Group (MSWG) and the Council of Europe Working Party on Pharmaceuticals and medical devices for the the revision of the Regulation N. 726/2004/EC. Today she represents WHO in the Scientific Advisory Committees of GARDP and of the AMR Action Fund as observer.
Timothy Jinks was appointed the Head of Infectious Disease Interventions in 2021 where he leads Wellcome’s work in advancing R&D for therapeutics and diagnostics, alongside research to support solutions for antimicrobial resistance. In his previous role, he designed and led Wellcome’s strategic priority area for combatting drug-resistant infections, deploying a budget of over £250 million. Before that, he was responsible for a portfolio of Wellcome projects to support early-stage product development, which covered therapeutics, diagnostic and devices across several therapeutic areas, particularly infectious diseases and oncology. He is a Member of the CARB-X Joint Oversight Committee, Executive Board Member of VALUE-Dx, Member of the Longitude Prize Committee and Representative Member to the US Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria. Prior to joining the Trust in 2012, he accumulated over a decade of industry experience both in biologic therapeutic R&D and latterly as a consultant providing business development, licensing and commercial research services. He is a chemist-turned-molecular biologist, who holds a BS Chem from the University of Georgia and a MA and a PhD from Princeton University. In his academic career, he acquired extensive academic research experience at Harvard Medical School, Dana Farber Cancer Institute and the MRC National Institute for Medical Research.
Our CEO, Dr. Henry Skinner, joins the Fund from Tekla Capital Management, where he was Senior Vice President, Venture. Prior to joining Tekla, Dr. Skinner Served as Deputy Head and Managing Director of Novartis Venture Fund. In addition, Dr. Skinner has been CEO of SelectX Pharmaceuticals and NeoGenesis Pharmaceuticals and has held positions in Business Development for Novartis Institutes for Biomedical Research, Pfizer, Pharmacia, Pharmacia & Upjohn and Lexicon Genetics. Dr. Skinner was a postdoctoral fellow at Baylor College of Medicine in the department of Human and Molecular Genetics, earned his Ph.D. in Microbiology and M.S. in Biochemistry from the University of Illinois and M.S. and B.S. in Biology/Biotechnology from Worcester Polytechnic Institute.
Dr. Richard Soll is presently Senior Advisor, Strategic Initiatives for the Research Service Division at WuXi AppTec and Head of the WuXi office in Boston, Massachusetts. He has held various leadership roles at WuXi as Senior Vice President including head of the medicinal chemistry unit known as the International Discovery Service Unit, business development, and corporate alliances.
Dr. Soll’s contributions led to the discovery of the HCV NS5A inhibitor elbasvir (a component of Zepatier®) in the Merck-WuXi partnership, the JAK2 inhibitor fedratinib at TargeGen which formed the basis of the $7B partnership between Celgene and Impact Biomedicines, and more than 10 other clinical stage drugs throughout his career.
Dr. Soll is currently a board member at Simcha Therapeutics, an board observer at the Accelerator Life Science Parnters, and an advisory board member with the Blavatnik Center for Drug Discovery at Tel Aviv University, the Children’s Tumor Foundation, and the Pistoia Alliance.
Dr. Soll was CSO / VP of R&D at TargeGen and was VP of Chemistry at 3-Dimensional Pharmaceuticals. He started his career at Ayerst Research Labs and was trained as a synthetic chemist at Dartmouth and Harvard.
Over 20 years of experience in pharmaceutical development and manufacturing. Played important roles in R&D and commercialization of multiple innovative drugs for global launches. Awarded by The Medicine Maker's 2019 & 2020 Power List as one of the global top inspirational medicine makers driving the industry forward. Formerly Director of Technical Operations at Vertex. B.S. in Chemistry from Peking University and Ph.D. in Organic Chemistry from the University of Minnesota.
Stephen M. Hahn, M.D., is CEO-Partner of Flagship Pioneering and Chief Executive Officer of Harbinger Health. Dr. Hahn served as the 24th U.S. Food and Drug Administration (FDA) Commissioner from 2019 to 2021 overseeing COVID and non-COVID regulatory affairs. Previously, Dr. Hahn held executive roles at MD Anderson Cancer Center, including chief medical executive and deputy president and chief operating officer, as well as other positions. Prior to joining MD Anderson, Dr. Hahn led radiation oncology at the University of Pennsylvania’s Perelman School of Medicine. Dr. Hahn earned his M.D. from Temple University and B.A. in Biology from Rice University.
Rana Al-Hallaq, PhD is Executive Director and Partner at Pfizer Ventures. Rana leverages her preclinical, clinical, and business development experience to assess, invest in, and manage equity investments for Pfizer Ventures. She currently has responsibility for Pfizer’s investments in ReCode Therapeutics (Menlo Park, CA; Dallas, TX), Vivet Therapeutics (Paris, France), Mitokinin (San Francisco, CA), Autifony Therapeutics (Stevenage, UK), Blade Therapeutics (South San Francisco, CA), RefleXion Medical (Hayward, CA), Montis (Leuven, Belgium), Biograph55 (San Francisco, CA), Jnana Therapeutics (Boston, MA), Triplet Therapeutics (Cambridge, MA), Arkuda (Cambridge, MA), and the Dementia Discovery Fund (London, UK). Prior to her current role, Rana was a Transactionalist in Worldwide Business Development at Pfizer where she was responsible for negotiating and transacting licenses, acquisitions, and partnerships across therapeutic areas. Rana joined Pfizer in 2015 as an Early Candidate Clinical Lead where she advised early clinical programs in CNS to ensure alignment with business strategies. Prior to joining Pfizer, she held roles at Allergan (formerly Actavis, formerly Forest Laboratories), first in Clinical Development Psychiatry as scientific and operational lead on Phase 2 and Phase 3 studies investigating novel treatments for Major Depressive Disorder and schizophrenia, and later in Business Development where she assessed and executed on a number of acquisitions and licenses across therapeutic areas. She began her training as a research fellow at the National Institutes of Health. Rana graduated Summa Cum Laude and Phi Beta Kappa with a BA in Biology from Hamilton College and holds a PhD in Neuroscience from Georgetown University Medical Center.
Laurence is a Partner in the Dementia Discovery Fund (DDF) and has supported the funding and formation of numerous DDF companies developing transformational new medicines for dementia. He joined SV Health Investors in 2016 having played an active role in setting up DDF.
Prior to joining the DDF, Laurence was Head of Investment Management in Worldwide Business Development at GSK where he was responsible for managing GSK’s venture investment portfolio, covering both direct equity positions as well as a venture fund-of-funds portfolio. In addition, he led licensing transactions for the pharma R&D business. Prior to GSK, Laurence worked in business development at biotech companies Syntaxin and MorphoSys. Laurence received his Master’s degree in Biochemistry and Molecular Biology from the University of Auckland, New Zealand, his PhD in Biochemistry from the University of Tübingen, Germany, and an MBA from Cambridge.
Prof. dr. Philip Scheltens studied at the VU University Amsterdam, Netherlands, gaining his MD in 1984, and PhD in 1993. He became Professor of Cognitive Neurology and founder of the Alzheimer Center at Amsterdam University Medical Centers in 2000. Currently his main activity is managing partner of the LSP Dementia Fund at EQT Life Sciences, that he started in 2020.
He has been the (inter)national PI for over 35 studies, including phase 1-3 multicenter clinical trials. He supervised >75 PhD theses since 2000. He founded the Dutch national plan against dementia and served as chair of the board. He is co-editor-in-chief of Alzheimer’s Research & Therapy and co-leads various EU projects. He authored over 1100 peer reviewed papers and > 75 book chapters and co-edited several major text books.
He is member of the Royal Dutch Academy of Arts and Sciences (KNAW) since 2011. In 2016 he was awarded the European Grand Prix for Alzheimer’s Research. In 2020 he was Knighted in the Order of the Netherlands Lion by the King of the Netherlands. In 2021 he was elected honorary member of the European Academy of Neurology and was appointed chair of the World Dementia Council.
Christina Isacson is a Partner of Lightstone Ventures and focuses on investments in the biopharmaceutical sector. Christina has spent over 17 years in the biotech industry across operational roles and in venture capital. She brings experience in creating, launching, building and operating early stage biotechnology companies including Magenta Therapeutics (NASDAQ:MGTA) and Decibel Therapeutics (NASDAQ:DBTX).
Before joining Lightstone in 2021, Christina was part of the founding team and Chief Business Officer at Magenta Therapeutics where she was accountable for portfolio strategy and management, program management, business development, alliance management and commercial strategy. Prior to Magenta, Christina was Principal at Third Rock Ventures, an early-stage life sciences venture capital firm. At Third Rock, Christina focused on new company formation, due diligence, and led business development efforts more broadly on behalf of Third Rock. Prior to being part of the founding teams of Magenta and Decibel, Christina held operational roles at Ironwood Pharmaceuticals (NASDAQ:IRWD) in corporate development. In addition, she has held venture roles with Boston University’s Technology Development Fund and with Accelerator Corp (Fund I).
Originally trained as a Ph.D. in Neuroscience, leading the integration of science and medicine with business is a fundamental objective in her career.
Todd Sherer, PhD, is Executive Vice President, Research Strategy of The Michael J. Fox Foundation for Parkinson's Research (MJFF). Formally trained as a neuroscientist, he is deeply focused on the organization's research strategy, charting a course for the coming era of Parkinson’s discovery and drug development. Dr. Sherer’s role includes contributing to key research initiatives such as MJFF’s relaunched landmark clinical study, the Parkinson’s Progression Markers Initiative (www.ppmi-info.org), and collaborating with MJFF’s ever-increasing roster of partners in biopharma and government. He joined the Foundation staff in 2004 and served as Chief Executive Officer for 10 years, from May 2011 to May 2021.
Andrew Siderowf, MD MS is the Hurtig-Stern Professor of Neurology and the Chief of the Movement Disorders Division in the Penn Perelman School of Medicine Department of Neurology. He received his MD at Duke University, residency training at the Hospital of the University of Pennsylvania and fellowship training in Movement Disorders and Experimental Therapeutics at the University of Rochester. Dr. Siderowf’s clinical practice focuses on the diagnosis and management of patients with Parkinson’s disease and related disorders. His research addresses the organization and conduct of clinical trials, particularly the use of biomarkers as outcome measures.
Simone serves as Vice President and Editor in Chief, bringing experience from both industry and academia in translational science, where she focused for over 15 years on the scientific, commercial and strategic considerations for advancing laboratory discoveries to products for patients.
Since joining BioCentury in 2013, Simone has written and edited on innovation from idea to patient, most recently serving as Executive Editor. Previously, she was a director of translational research at Nektar Therapeutics and a senior managing consultant at Exponent Inc., where she specialized in projects for the biopharma industry. Simone serves as an adviser on multiple university translational programs, including initiatives at the University of California and Stanford University. Simone is also active in programs to advance women's careers; she is a board member of Women In Bio and served as its President in 2013-14.
Simone is a Fulbright scholar and performed a post-doc at the University of California San Francisco. She holds a Ph.D. in Molecular Pharmacology from the Weizmann Institute of Science, and an M.A. and B.A. in Pharmacology from Cambridge University.
Dr. Sekar Kathiresan is co-founder and CEO of Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. Dr. Kathiresan is a cardiologist and scientist who has focused his career on understanding the inherited basis for heart attack and leveraging those insights to improve the care of cardiovascular disease. Based on his groundbreaking discoveries in human genetic mutations that confer resistance to cardiovascular disease, Dr. Kathiresan co-founded Verve Therapeutics with a vision to create a pipeline of single-course, gene editing therapies focused on addressing the root causes of this highly prevalent and life-threatening disease. Today, Verve is advancing two initial programs that target PCSK9 and ANGPTL3, respectively – genes that have been extensively validated by Dr. Kathiresan and others as targets for lowering blood lipids, such as low-density lipoprotein cholesterol, which is a major driver of cardiovascular disease.
Prior to joining Verve, Dr. Kathiresan’s roles included director of the Massachusetts General Hospital (MGH) Center for Genomic Medicine, director of the Cardiovascular Disease Initiative at the Broad Institute and professor of medicine at Harvard Medical School. There, Dr. Kathiresan’s research laboratory focused on understanding the inherited basis for blood lipids and myocardial infarction. For his research contributions, he has been recognized by the American Heart Association with its highest scientific honor - a Distinguished Scientist Award and by the American Society of Human Genetics with the 2018 Curt Stern Award.
Dr. Kathiresan graduated summa cum laude with a B.A. in history from the University of Pennsylvania and received his M.D. from Harvard Medical School. He completed his clinical training in internal medicine and cardiology at MGH and his postdoctoral research training in human genetics at the Framingham Heart Study and the Broad Institute.
Claudia Ulbrich, an MD and health economist by training, is the CEO of Cardior Pharmaceuticals, a company pioneering the discovery and development of RNA-based therapeutics designed to prevent, repair and reverse the world’s number one cause of death, cardiovascular diseases.
With more than 25 years of management expertise in private and public biotech companies, Claudia is an integrative, experienced leader guiding international, cross-functional teams based on a broad range of experience in M&A, transaction management and consulting. She brings a strong network in venture capital, academia, and industry. Claudia combines a high level of commercial competence with a sound knowledge of medical affairs and drug development all along the valuation chain. With her excellent abilities in financing, transactions to 2bn EUR and strategy she is responsible for general management including P&L, corporate development, and investor relations. In 1998, Claudia founded her first biotech company LipoNova AG (IPO in 2006) after which she served as Co-Founder, executive advisor, and interim manager of several international biotech companies, such as uniQure N.V., InoCard GmbH and t-cell Europe GmbH. Having worked as Senior Advisor at PricewaterhouseCoopers she started her own consulting business in 2008. Claudia holds several Board positions in relevant public and trade organizations.
Christopher de Souza shares responsibility for operations at Broadview Ventures, including sourcing and screening of investment opportunities, deal structuring and portfolio company board involvement. He leverages over 30 years of experience in biopharmaceutical R&D, business development and strategy to help meet the Broadview Ventures mission.
Prior to Broadview, Christopher was at Novartis and SkyePharma. He has an MBA from Rutgers University and a PhD from Louisiana State University with post-doctoral training at “The Upjohn Company” and the Joslin Diabetes Center/Harvard Medical School.
He currently serves on the boards of Acesion, Gila Therapeutics and Mellitus.
Michael E. Mendelsohn, MD is the Chairman of Cardurion Pharmaceuticals, a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics for the treatment of heart failure and other cardiovascular diseases. Dr. Mendelsohn is an internationally recognized cardiovascular physician-scientist, and a research and business leader with broad experience in both academia and industry. Dr. Mendelsohn received his undergraduate degree in Chemistry and English from Amherst College and his MD from Harvard Medical School (HMS). He completed training in both Internal Medicine, and Cardiovascular Medicine at Brigham and Women's Hospital (BWH) and HMS and spent 25 years as an academic cardiovascular physician-scientist in Boston. From 1988-1993, Dr. Mendelsohn was a member of the BWH Cardiology Division faculty and an assistant professor of medicine at HMS. In 1993, Dr. Mendelsohn moved to Tufts Medical Center, where he created and served as the first executive director of the Molecular Cardiology Research Institute, a research department pursuing basic and translational cardiovascular research. He was the first recipient of the Elisa Kent Mendelsohn Professorship of Molecular Cardiology and Medicine at Tufts, and in 2008, became the first Chief Scientific Officer at Tufts. In 2010, Dr. Mendelsohn became the Global Head of Cardiovascular Diseases at Merck & Co., with end-to-end responsibilities for scientific strategy, drug discovery research, and both clinical and business development. Dr. Mendelsohn founded Cardurion in 2016. He is currently also a Board Director for Foghorn Therapeutics and Cyclerion Therapeutics, and a Professor of Medicine at Tufts University School of Medicine.
Dr. Dave Madge is Vice President of Discovery Services in WuXi AppTec. In this role Dave leads a portfolio of drug discovery initiatives across multiple therapeutic areas and modalities. Prior to joining WuXi AppTec, in 2014, Dave was VP, Research, for the ion channel drug discovery company Xention Ltd, in Cambridge, UK, developing new molecules for cardiovascular and respiratory disorders. Before Xention Dave was based at University College London, as part of an integrated biomedical research group, and was responsible for developing new therapeutic discovery projects into funded biotech companies. Dave has a PhD in Medicinal Chemistry from Imperial College, London, and started his career at The Wellcome Foundation in the medicinal chemistry team.
Dr. Adam Friedman is an accomplished physician, scientist and life sciences entrepreneur with extensive experience in oncology. He currently serves as President, Corporate Strategy & Business Development, which follows his former role as interim CEO of Scorpion Therapeutics.
Prior to joining the company, Dr. Friedman served as Director at Serien Therapeutics, a next-generation immuno-metabolism company, and founder of Vivid Biosciences, an oncology platform discovery company, where he served as President and Chief Executive Officer. As an entrepreneur-in-residence at Atlas Venture, he helped launch several portfolio companies exploring new areas of biology, including Raze Therapeutics, a next-generation cancer metabolism company, where he served as Founder & Director of Corporate Development. He has authored multiple peer-reviewed publications on systems biology, cell signaling, genetics and cancer biology.
Dr. Friedman received his B.A. in molecular biology from Princeton University and received both his M.D. and Ph.D. in genetics from Harvard Medical School. Dr. Friedman completed residency training in pediatrics at Boston Children’s Hospital.
Luba is a veteran biotech, pharmaceutical, tech, and life sciences investor and company builder. Luba serves as the Managing Partner of the Dana Farber Cancer Institute Venture Fund, Binney Street Capital (BSC), which she has built and launched. She is also the CEO of one of BSC’s portfolio companies Kojin Therapeutics, which is discovering and developing novel therapeutics in oncology, fibrosis, and immune modulation. She is a professor at Harvard University in the School of Engineering and Applied Sciences. Luba has previously served in leadership roles at Google Life Sciences (Verily) and as Vice President of Global Business Development and Mergers & Acquisitions at Roche, where she also established and led the East Coast Innovation Hub. Luba has led $5B+ in deals and investments across multiple therapeutic areas and life sciences and tech sectors globally. She has also co-founded biotech and digital health companies in the immunotherapy, AI/ML, women's health and microbiome space, including Luca Biologics.
She has served on multiple public, private, and non-profit boards, including the Massachusetts Biotechnology Council (MassBio), Kojin Tx, Brooklyn ImmunoTherapeutics, BenchSci, In8Bio, and OS Fund, a SPAC. She has advised leading academic centers globally including the CEO of the Dana-Farber Cancer Institute as well as the Director of the Wyss Center for Bio and Neuroengineering in Geneva. She is a Thought Leader for the New England Journal of Medicine (NEJM) Catalyst and serves on Investor Committee for the National Cancer Institute. Luba is also a former litigator and regulatory, policy, and IP expert, having started her career at Wilmer Cutler Pickering Hale and Dorr. She is a recipient of several awards and honors for her work in the community, including the Science Club for Girls Catalyst Award for her commitment to advocating for women in science and technology.
Raj Chopra is currently Venture Partner, Head of Oncology at Apple Tree Partners. He was previously Director of the Cancer Research UK Cancer Therapeutics Unit and Head of the Division of Cancer Therapeutics at the Institute of Cancer Research in London. He has had experience of working both in academia and industry having been Director of Hematological Oncology, Christie Hospital in Manchester and subsequently in the Oncology Therapeutic area at AstraZeneca.
From 2009-2016, he was leader of the Executive R&D Team and Corporate Vice President of Translational and Early Drug Development at Celgene Corporation, Summit, NJ, where he led a team of over 100 scientists in San Diego, San Francisco and Seville. There he was involved in a large number of drug discovery and development projects and part of a team that helped to define the mechanism of action of Thalidomide and its analogues. In addition, Raj was also involved in the New Drug Applications for pomalidomide (a second generation IMiD agent) and apremilast (a PDE4 inhibitor). Both drugs were approved in 2013 and 2014 respectively.
Raj was also a Non-Executive Director of Artios Pharma Ltd, which has been established to develop a next generation DNA Damage Response (DDR) target pipeline with the potential to transform cancer therapy and Co-Founder of Monté Rosa Therapeutics a Versant backed start up.
Raj is currently Chief Medical Officer of Marengo Therapeutics and sits on the Boards of the following ATP portfolio companies: Nereid Therapeutics, Initial Therapeutics, Adendra Therapeutics and Aulos Bioscience.
Key current research areas:
1. Haematological Oncology
2. E-3 ligase modulation
3. Zinc Finger Biology
Key current technologies/methodologies:
1. Drug Discovery
2. Targeted protein degradation
3. Complex 3-D cell culture models
Prior to Walking Fish, Dr. Williams founded and served as a director of Five Prime Therapeutics, Inc., a public biotechnology company, from January 2002 to January 2020, and served as its President and Chief Executive Officer from April 2011 to December 2017. Previously, Dr. Williams spent seven years at Chiron Corporation ("Chiron") a biopharmaceutical company, now known as Novartis Vaccines and Diagnostics, Inc., most recently as its Chief Scientific Officer. He also served on Chiron's board of directors from 1999 to 2001. Prior to joining Chiron, Dr. Williams was a professor of medicine at the University of California, San Francisco, and served as Director of the University's Cardiovascular Research Institution and Daiichi Research Center. Dr. Williams also has served on the faculties of Harvard Medical School and Massachusetts General Hospital and co-founded COR Therapeutics, Inc., a biotechnology company focused on cardiovascular disease. He is a member of the National Academy of Sciences and a fellow of the American Academy of Arts and Sciences. Dr. Williams was previously a member of the board of directors of COR Therapeutics, Inc., and Beckman Coulter, Inc., each of which was a public company during his service as a director. He currently serves on the Boards of Protagonist Therapeutics and Arcellx Therapeutics. Dr. Williams has also served as a venture partner of Quan Capital, LLP, a healthcare-focused venture capital firm, since October 2018. Dr. Williams received a B.S. from Rice University and an M.D. and a Ph.D. from Duke University.
KT Moortgat, PhD, is a healthcare venture capital investor and executive with a track record of venture investing, company incubation, and realized and unrealized value creation. She joined Droia Ventures in 2021 as Investment Partner, to expand and manage the firm’s portfolio of companies driving novel therapies to treat cancer and genetic disease. Prior to Droia, KT headed west coast investing activities at AbbVie Ventures, recognized as one of the most active pharma corporate venture investors. She was most recently responsible for seed to Series B investments in Ambagon Therapeutics, Nitrase Therapeutics, Quanta Therapeutics, Stemson Therapeutics, PACT Pharma, and has held additional board roles at Tizona (GILD), Trishula, and eFFECTOR (EFTR). Previously, she has held executive and consulting roles with multiple biotech companies, including as CEO; and founded and led the hub of entrepreneurship at UC San Francisco.
Trained in science as an undergraduate at UC Berkeley, KT earned a PhD for research at the Salk Institute. She was a NIH Predoctoral Fellow, and a Sloan Postdoctoral Fellow. She is a member of the Industry Advisory Group at UC Berkeley’s Bakar Labs.
Jocelyne has an extensive background working in businesses from science and engineering technology sectors and has used this experience to help shape OXGENE in recent years. Prior to joining OXGENE Jocelyne was Chief Revenue Officer at EYOTO, where she determined product strategy and was responsible for a complete rebrand of the organisation as well as building a sales and marketing team. Prior to EYOTO, Jocelyne was VP-Commercial Strategy for P2i. In this role she set the direction for and grew a team to support the sales organisation with business analysis and marketing. Her early career was spent with Orange Business Services where she gained a range of experience in product, revenue and commercial management. Jocelyne holds a Masters in Engineering from the University of Southampton.
Jocelyne is motivated by the people around her at OXGENE and values the diverse and supportive culture of the business. She finds pleasure in recognising the skills of others and helping her colleagues to develop and achieve their goals. Jocelyne has two teenage children and enjoys being active, spending her free time running, cycling, and doing yoga. She enjoys setting challenges for herself, like running 100 miles in March for two consecutive years to raise money for charity.
Rick serves as WuXi’s Chief Operations Officer for the US, UK, and European operation. He has been with WuXi since October 2018 and works out of the Boston, Massachusetts office.
Prior to joining WuXi, Rick held roles of increasing responsibility at Pfizer where he began his career as the Director of Cancer Medicinal Chemistry in 1999. After four years in that role, he moved into operations as an Executive Director and established the companies first, integrated Chemistry Outsourcing strategy. Four years later, he was promoted to Vice President of External operations, with responsibilities for managing the external network of suppliers, academics and CROs that enabled Pfizer’s R&D engine with services, data, and assets. During his time at Pfizer, Rick spend one year in Sandwich UK (2002-2003) as Director of Sex Health Medicinal Chemistry, and a year in Shanghai (2011) to establish Pfizer’s Anti-infective Research unit in Shanghai.
Rick is a Chemist by training with a PhD in Organic Chemistry from the University of Notre Dame. He was a National Institute of Health (NIH) Post-Doctoral Investigator at Harvard under the direction of Professor E. J. Corey: the 1990 Nobel Prize winner in Chemistry. Prior to joining Pfizer, he worked at Bayer as a Medicinal Chemist at Bayer’s West Haven, CT campus and spent two years at their Wuppertal, Germany R&D site.
William N. (Bill) Hait is Executive Vice President, Chief External Innovation, Medical Safety and Global Public Health Officer, and a member of the Johnson & Johnson Executive Committee. Bill oversees the Research and Development Management Committee that focuses on talent development and best-practice sharing within the Company’s R&D community, as well as Company efforts to advance mental health, improve healthcare for the world’s most vulnerable and underserved populations, and meet its obligations around product safety and ethical research, aligned with Our Credo.
Dr. Hait joined J&J in 2007 and served as Global Therapeutic Area Head for Oncology from 2009 to 2011, and then as Global Head, Janssen Research & Development, from 2011 through 2018. Before that, he was the founding Director of The (Rutgers) Cancer Institute of New Jersey. From 1993 to 2007 he was Professor of Medicine and Pharmacology and Associate Dean for Oncology Programs at the University of Medicine and Dentistry of New Jersey -- Robert Wood Johnson Medical School.
Dr. Hait joined the Yale University School of Medicine faculty in 1984 and became Associate Professor of Medicine and Pharmacology, Chief of the Division of Medical Oncology, Associate Director of the Yale University Comprehensive Cancer Center, Director of the Breast Cancer Unit and Co-Director of the Lung Cancer Unit. He is Board Certified in Internal Medicine and Medical Oncology.
He devoted time to numerous advisory and editorial boards, served in a range of scientific functions, societies and committees, was elected President of the American Association for Cancer Research (2007 – 2008) and has received numerous awards and honors.
Julie Grant is a General Partner at Canaan, a tech and healthcare venture capital fund with $5B assets under management. She leads investments and company formation efforts in biopharma and digital health companies that tangibly improve patient care. Since joining Canaan in 2013, Julie has incubated, financed, and supported investments in multiple new biopharmaceutical companies including Day One (DAWN), Nocion, Synthekine, Protagonist (PTGX), Cellular Research (Acquired by Becton Dickinson), Dermira (Acquired by Eli Lilly), Labrys (Acquired by Teva), CytomX (CTMX), Unchained Labs (Acquired by The Carlyle Group), Genome Medical, Glooko, and Truveris.
Prior to joining Canaan, Julie worked at Genentech bringing new oncology products to market in roles spanning business development, cross functional management and commercial. She holds an M.B.A. from Stanford’s Graduate School of Business, a M.Phil. from Cambridge University in BioScience Enterprise and a B.S. in Molecular Biophysics and Biochemistry from Yale University.
Dr. Danny Soon is Chief Executive Officer at the Consortium for Clinical Research and Innovation, Singapore (CRIS) and concurrent Executive Director at the Singapore Clinical Research Institute (SCRI). As the inaugural CEO, Danny has the responsibility of bringing together five research programmes and platforms under the auspices of CRIS, promulgating synergies and strategies, building corporate functions to service the entire entity.
Danny was previously Executive Director, Biomedical Research Council (BMRC) in A*STAR. His team in BMRC was responsible for incepting and coordinating efforts and programmes in drug development, precision medicine, medical technology and biomanufacturing. Previously, Danny also held the role of founding and Acting CEO of the Experimental Biotherapeutics Centre. In this role, where he and his team were responsible for setting up a brand new centre for biotherapeutics development.
Danny has long experience in drug development, having worked at Eli Lilly and Company for 15 years, where he headed up the Lilly-NUS Centre for Clinical Pharmacology (LNUS). As the Managing Director and Principal Investigator, Danny had responsibility and oversight for all clinical Phase 1 studies conducted and operations in the unit. Studies conducted included first-in-human studies, biomarker development work, human physiology investigations and pivotal registration PK studies, in neuroscience, diabetes, musculoskeletal and cardiovascular therapeutic areas.
As the CEO of MediSix Therapeutics based from our headquarters in Singapore, Andrew Bruce leads a strong and growing team in further developing the work of Professor Dario Campana in T-cell engineering. Andrew is an accomplished professional with more than 36 years in the pharmaceutical industry.
He has gained broad experience across a range of functions from sales and marketing to supply chain and logistics, medical affairs, therapy area strategy and corporate development. Andrew has held leadership positions within the pharmaceutical, biotech and medical consulting industries, in addition to commercial and strategy roles, including founding and subsequent sale of a global specialist medical consulting leader.
He moved to Singapore in March 2021. Andrew gained his BSc at the University of Bradford.
Professor Wee Joo CHNG is Director of the National University Cancer Institute, Singapore and Group Director of Research, at the National University Health System. He is the Provost’s Chair Professor and Vice-Dean of Research of the Yong Loo Lin School of Medicine, and Deputy Director and Senior Principal Investigator of the Cancer Science Institute of Singapore, at the National University of Singapore.
He is a member of many international professional committees, such as the International Myeloma Working Group and the Asian Myeloma Network. He is also involved in a number of Grant Review Committees, Conference Organising Committee, Advisory Boards and Steering Committees of Global Clinical Trials. He has authored more than 300 publications in many reputed journals, and actively participates in clinical trials and has delivered talks in many national and international conferences. He has won multiple awards for his outstanding achievements in translational research both locally and internationally including the International Myeloma Foundation’s Brian GM Durie Outstanding Achievement Award, the National Medical Excellence Outstanding Clinician Scientist Award, the National Medical Research Council Senior Translational Research (STaR) Award, the National University of Singapore Young Researcher Award, and the Celgene Future Leaders in Haematology Award.
Dr Koh Boon Tong joined A*STAR as Executive Director of BTI on 3 May 2021. With over 30 years of experience in the private sector, he has managed specialty chemicals and API operations and businesses in Asia, particularly in China and India.
Dr Koh comes onboard with deep expertise in managing project startups, plant operations, technical applications and development labs. He sat on numerous Boards, including JVs, and manages both operational and business teams across Asia. He spent many years in China setting up operations and growing strategic businesses.
Boon Tong graduated from NUS (Chem Eng) and started BTU in 1990, which is now BTI.
Assistant Professor Francesca Lim is a Senior Consultant Hematologist at Singapore General Hospital and the Deputy Head and Principal Lead of Education of the SingHealth Duke-NUS Cell Therapy Centre (SDCT). She is also the Assistant Medical Director at the Cell Therapy Facility, Health Science Authority (HSA).
Dr. Lim spent 2 years training at MD Anderson Cancer Center on CAR T cell therapy particularly on CAR NK cell therapy under Professor Katy Rezvani as well as in the Good Manufacturing Processing Facility (GMP). Dr Lim currently leads the Clinical CAR-T Cell Therapy Program at the Singapore General Hospital and has been highly instrumental in supporting and coordinating the Immune Effector Cell Therapy Program at SingHealth at the research and translational level. Dr Lim is currently involved in several educational CAR T activities around South East Asia and is actively involved in fostering closer relationships with Cross Boarder Institutions seeking to develop their Clinical CAR-T Cell Program."
Dr Yann Chong Tan is a successful inventor and biotech entrepreneur who has co-founded a Nasdaq-listed biotech. He is currently Managing Director at EVX Ventures, a venture builder, CEO of Nuevocor, a gene therapy biotech company focused on curing genetic cardiomyopathies, and CSO of Cargene Therapeutics, a biotech company focused on curing diseases using oligonucleotides as the treatment modality.
Dr Tan was previously the Chief Innovation Officer at the Genome Institute of Singapore, A*STAR. As CIO, Dr Tan led the implementation of strategies to create new spin-offs, resulting in spinning off 2 biotech companies, Nuevocor and Cargene Therapeutics, with Nuevocor having the largest initial funding round for a Singapore biotech spinoff to date. He was also co-founder and former Chief Technologist at Atreca, a biotech company spun off from his PhD research, and the inventor on multiple patents which are the foundation of Atreca’s technology. He led Atreca’s core foundational Immune Repertoire Capture (IRC) antibody discovery team and discovered the antibody now in clinical trials. Atreca is listed on Nasdaq.
Dr Tan graduated with a Bachelor of Science in Biology (summa cum laude) from Duke University and obtained his Doctor of Philosophy in Immunology from Stanford University.
Steve Bates has been leading the UK BioIndustry Association as CEO since 2012. He currently chairs the International Council of Biotech Associations and has been a board member of Europabio since 2015. He sits on the UK’s Life Sciences Council. Steve is the visible face of the vibrant UK life sciences industry to government and media. Steve was a founder member of the UK Government’s Vaccine Taskforce in the Covid crisis, sitting on its steering Board alongside Kate Bingham.
Steve has championed, with government, effective industrial incentives like the Biomedical Catalyst, which have crowded in private sector investment into UK SMES. He has forged several links for the sector across the USA, Europe and in China. In his time at the BIA, Steve has developed new member groups focused on cell and gene therapy, genomics and engineered biology. A strong advocate of partnership working, Steve champions sector collaboration with research charities and academia. Proud to lead an organisation with a diverse Board with over 40% female representation, Steve is committed to next generation talent and developing the skills needed for the sector to flourish.
Before the BIA, Steve worked for Genzyme and was advisor to the UK Government of Tony Blair. He was made OBE for services to innovation in 2017 and became a Fellow of the Academy of Medical Science in 2020.
Since April 2020, Mike has been the Global Head of Life Sciences & Healthcare Thought Leadership at Clarivate. Prior to that he was best known as both a journalist and analyst, writing, analyzing and commenting on the life sciences industry for more than 35 years. He has held editorial and content leadership roles at various publications and organizations across the industry. In 2010, he was named European Mediscience Commentator of the Year and has been on the short list on other occasions in the past decade. In 2018, he was fourth on Labiotech.EU’s list of “Biotech Leaders You Should Know in the UK’s Golden Triangle.”
Billy Boyle is an engineering graduate from the University of Cambridge. He is one of the original co-founders of Owlstone Inc, spun out of Cambridge in 2004 with the goal of developing the applications of field asymmetric ion mobility spectroscopy (FAIMS).
Billy started to focus on the medical applications of FAIMS technology after his wife, Kate, was diagnosed and later died of colon cancer as a result of a late diagnosis. He worked closely with clinical partners who integrated FAIMS technology across a broad spectrum of research studies.
Positive results helped to spin-out, and secure initial funding for, Owlstone Medical. With ongoing clinical and commercial success, Billy led this process and became the founding CEO upon the close of a $7M investment in March 2016. The mission of Owlstone Medical is to save 100,000 lives and $1.5B in healthcare costs. As of 2021, the company has secured over $150M of investment.
Owlstone Medical has developed Breath Biopsy with the goal of creating non-invasive breath tests to support early detection and precision medicine of diseases including cancer, asthma, COPD and liver disease. The company works with leading academic institutions and industry leaders such as Astra Zeneca, J&J and GSK.
Billy is also a judge for the Cancer Research UK (CRUK) Pioneer award and a trustee of the Linacre Institute. He was made a Fellow of the Royal Academy of Engineering in 2020 and an MBE in 2021.
Kathryn has over 25 years experience in early and late drug development across multiple indications and platforms. She was partner at Takeda Ventures, Inc. and Head of Oncology Cell Therapy Development at Takeda Pharmaceuticals where she built capabilities and oversaw a cutting edge oncology cell therapy portfolio. Prior to that, she held several roles at Sanofi Genzyme and built a two decade career at Hoffman – La Roche, Roche Molecular Systems, Eli Lilly and Syndax, contributing to the approval of 6 new cancer therapies and expansion of multiple indications.
Jack O’Meara is Co-Founder & CEO of Ochre Bio, a genomics-based drug discovery company developing RNA therapies for chronic liver disease patients. Jack is a biomedical engineer by training, with a background in bringing new healthcare and life sciences products to market.
Ochre uncovers new biological pathways by using advances in 'deep phenotyping', and then validates novel targets in human livers kept alive on machines. In doing so, Ochre aims to improve the likelihood that the RNA therapies taken into the clinic will successfully improve patient lives. With labs operating in Oxford, New York and Taipei, Ochre was founded on two decades of experience in liver genomics and bringing advanced therapies to market.
Having always been fascinated by the intersection of healthcare, technology and business, Jack co-founded Ochre to translate breakthroughs in transplant medicine and genomics, with a long-term vision for chronic, age-related diseases.
Ryan founded Oxford Genetics (trading as OXGENE) in 2011, after earning a degree in genetics and a PhD in gene therapy from Oxford University. The idea behind the company was to simplify and standardise the process of DNA engineering using a proprietary DNA plasmid platform called SnapFast™. Ryan used his background in virology to guide and grow the business through a series of strategic changes that deployed the SnapFast™ technology for cell and gene therapy discovery and manufacturing applications. He has over 20 peer reviewed papers and is the inventor on more than 100 international patent applications. In 2021, Ryan led the sale of the OXGENE to WuXi Advanced Therapies. He is currently the Chief Scientific Officer for WuXi Advanced Therapies and OXGENE.
Ben is a psychiatrist, scientist, and investor who has been working at GV since 2014. Ben’s investments focus on healthcare delivery and neuropsychiatric therapeutics and include Aspire (acquired by Anthem), Rodin (acquired by Alkermes), Ready, Carebridge, and Cerevance.
In a past life, Ben worked as an intern at "The Daily Show" with Jon Stewart. Since then, he completed psychiatric training at Massachusetts General Hospital and Mclean Hospital, the top and second-ranked departments of psychiatry in the United States. He also co-founded a non-profit to fund, build, and operate a primary school for AIDS orphans in Tanzania.
Ben received his M.D. from Harvard Medical School, MBA from Harvard Business School, and B.A. with honors from Dartmouth College, where he was a member of the football team.
Vineeta Agarwala, MD, PhD, is a General Partner at Andreessen Horowitz where she leads investments for the firm’s bio fund across therapeutics, diagnostics, and digital health, with a focus on companies that are leveraging unique datasets to improve drug development and patient care delivery. She serves on the board of BigHat Biosciences.
Prior to joining a16z, Vineeta has held many different roles in the healthcare space: as a physician taking care of patients; as an operator at tech-driven healthcare companies; and most recently as a venture investor on the GV (Google Ventures) life sciences team, focused on biotech companies with a data-driven approach. Previously, she was an early data scientist at Kyruus; a management consultant for biotech, pharmaceutical, and medical device clients at McKinsey & Co; and a Director of Product Management at Flatiron Health, where she led the company’s partnership with Foundation Medicine to integrate real-world clinical and genomic data into national-scale database products to accelerate drug development and research in oncology. She has collaborated with academic researchers at Cold Spring Harbor Laboratory, Lawrence Livermore National Laboratory, and the Broad Institute, where she did graduate work in computational biology and human genetics.
Vineeta holds a B.S. in biophysics from Stanford University, and MD and PhD degrees from Harvard Medical School / MIT. She completed her clinical residency at Stanford, and is board certified in internal medicine. Vineeta continues to see patients at Stanford as an adjunct clinical professor in the Division of Primary Care and Population Health.
Rohit Chandra, PhD, is the Chief Digital Officer at Cleveland Clinic since February 2022, and leads digital technology and innovation throughout the global health system.
Dr. Chandra joined Cleveland Clinic from Sunshine Products, a technology startup in Palo Alto, Calif., where he was vice president of engineering. Prior to that, he was senior vice president of Search and Advertising at Verizon Media, where he was responsible for bringing together products and teams from Yahoo and AOL after their acquisitions by Verizon. During his 13 years at Yahoo, he helped build technology for search and advertising products in a variety of engineering leadership roles.
Dr. Chandra holds a bachelor of technology degree from the Indian Institute of Technology, Kanpur, India, and a doctor of philosophy degree from Stanford University, both in computer science.
Daphne Koller is CEO and Founder of insitro, a machine learning-driven drug discovery and development company transforming the way drugs are discovered and delivered to patients. She was the co-founder, co-CEO, and President of online education platform Coursera, the largest platform for massive open online courses (MOOCs), which has reached over 100M learners worldwide. She is also the co-founder of Engageli, an interactive digital learning platform aimed at improving learning outcomes. Daphne was the Rajeev Motwani Professor of Computer Science at Stanford University, where she served on the faculty for 18 years, and where she remains an Adjunct Faculty member. She was formerly Chief Computing Officer of Calico, an Alphabet company in the healthcare space. She is the author of over 300-refereed publications appearing in venues such as Science, Cell, Nature Genetics, NeurIPS, and ICML, with an h-index of over 145. Daphne was recognized as one of TIME Magazine’s 100 most influential people in 2012 and Newsweek’s 10 most important people in 2010. She has been honored with multiple awards and fellowships during her career including the Sloan Foundation Faculty Fellowship in 1996, the ONR Young Investigator Award in 1998, the Presidential Early Career Award for Scientists and Engineers (PECASE) in 1999, the IJCAI Computers and Thought Award in 2001, the MacArthur Foundation Fellowship in 2004, the ACM Prize in Computing in 2008, the ACM AAAI Allen Newell Award in 2019, and the IEEE CS Women of ENIAC Computer Pioneer award in 2022. Daphne was inducted into the National Academy of Engineering in 2011 and elected a fellow of the American Association for Artificial Intelligence in 2004, the American Academy of Arts and Sciences in 2014 and of the International Society of Computational Biology in 2017. Her teaching was recognized via the Stanford Medal for Excellence in Fostering Undergraduate Research, and as a Bass University Fellow in Undergraduate Education.